CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) has earned an average rating of “Hold” from the six analysts that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $117.00.
CHEOY has been the subject of several recent analyst reports. Royal Bank Of Canada lowered CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 target price for the company. in a report on Thursday, July 16th. Jefferies Financial Group cut CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Canaccord Genuity Group downgraded shares of CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Finally, Zacks Research raised shares of CochLear from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd.
View Our Latest Analysis on CHEOY
CochLear Stock Up 0.9%
CochLear Company Profile
Cochlear Limited is an Australian medical device company that develops, manufactures and supplies implantable hearing solutions. Its products are designed for people with severe to profound hearing loss who may not receive sufficient benefit from conventional hearing aids.
The company’s portfolio includes cochlear implants, bone conduction hearing implants, and related sound processors, accessories, software and support services. Cochlear also provides rehabilitation resources, clinical support and ongoing product services intended to help recipients use and maintain their hearing systems.
Founded in 1981 and headquartered in Sydney, Australia, Cochlear serves customers through a global network spanning Australia, New Zealand, North America, Europe, Asia and other international markets.
See Also
- Five stocks we like better than CochLear
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
